Global Radiopharmaceuticals in Nuclear Medicine Market Overview And Scope:
Global Radiopharmaceuticals in Nuclear Medicine Market Size was estimated at USD 5052.79 million in 2022 and is projected to reach USD 6790.59 million by 2028, exhibiting a CAGR of 5.05% during the forecast period.
The Global Radiopharmaceuticals in Nuclear Medicine Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Radiopharmaceuticals in Nuclear Medicine utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group, Isotec, Inc. (Sigma-Aldrich), Lantheus Medical Imaging, Inc., Nordion, Inc., Ntp Radioisotopes (Pty), Ltd., Siemens Healthcare (Subsidiary Of Siemens AG), Taiyo Nippon Sanso Corporation, Urenco Limited, Rotem Industries, Ltd., Inc., Australian Nuclear Association And Technology Organization (ANSTO), Board of Radiation And Isotope Technology (BRIT), Institute of Atomic Energy Polatom Radioisotope Centre, Institute of Isotopes Co., Ltd., Institute Of Radioelement (IRE)
Global Radiopharmaceuticals in Nuclear Medicine Market Segmentation
By Type, Radiopharmaceuticals in Nuclear Medicine market has been segmented into:Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
By Application, Radiopharmaceuticals in Nuclear Medicine market has been segmented into:
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Radiopharmaceuticals in Nuclear Medicine market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Radiopharmaceuticals in Nuclear Medicine market.
Top Key Players Covered in Radiopharmaceuticals in Nuclear Medicine market are:
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories
Inc.
Cardinal Health
Inc.
Covidien
Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec
Inc. (Sigma-Aldrich)
Lantheus Medical Imaging
Inc.
Nordion
Inc.
Ntp Radioisotopes (Pty)
Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries
Ltd.
Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co.
Ltd.
Institute Of Radioelement (IRE)
Objective to buy this Report:
1. Radiopharmaceuticals in Nuclear Medicine analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Radiopharmaceuticals in Nuclear Medicine market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Radiopharmaceuticals in Nuclear Medicine Market by Type
5.1 Radiopharmaceuticals in Nuclear Medicine Market Overview Snapshot and Growth Engine
5.2 Radiopharmaceuticals in Nuclear Medicine Market Overview
5.3 Diagnostic Radiopharmaceuticals
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Diagnostic Radiopharmaceuticals: Geographic Segmentation
5.4 Therapy Radiopharmaceuticals
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Therapy Radiopharmaceuticals: Geographic Segmentation
5.5 Enriched Stable Isotopes
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Enriched Stable Isotopes: Geographic Segmentation
Chapter 6: Radiopharmaceuticals in Nuclear Medicine Market by Application
6.1 Radiopharmaceuticals in Nuclear Medicine Market Overview Snapshot and Growth Engine
6.2 Radiopharmaceuticals in Nuclear Medicine Market Overview
6.3 Diagnostic Application
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Diagnostic Application: Geographic Segmentation
6.4 Therapeutic Application
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Therapeutic Application: Geographic Segmentation
6.5 Research
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Research: Geographic Segmentation
6.6 Pharmaceutical
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Pharmaceutical: Geographic Segmentation
6.7 Other
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Radiopharmaceuticals in Nuclear Medicine Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Radiopharmaceuticals in Nuclear Medicine Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Radiopharmaceuticals in Nuclear Medicine Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 BRACCO IMAGING S.P.A.
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 CAMBRIDGE ISOTOPE LABORATORIES
7.4 INC.
7.5 CARDINAL HEALTH
7.6 INC.
7.7 COVIDIEN
7.8 PLC
7.9 ECZACIBASI-MONROL
7.10 FUJIFILM HOLDINGS CORPORATION
7.11 GE HEALTHCARE (SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
7.12 IBA GROUP
7.13 ISOTEC
7.14 INC. (SIGMA-ALDRICH)
7.15 LANTHEUS MEDICAL IMAGING
7.16 INC.
7.17 NORDION
7.18 INC.
7.19 NTP RADIOISOTOPES (PTY)
7.20 LTD.
7.21 SIEMENS HEALTHCARE (SUBSIDIARY OF SIEMENS AG)
7.22 TAIYO NIPPON SANSO CORPORATION
7.23 URENCO LIMITED
7.24 ROTEM INDUSTRIES
7.25 LTD.
7.26 INC.
7.27 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO)
7.28 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT)
7.29 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE
7.30 INSTITUTE OF ISOTOPES CO.
7.31 LTD.
7.32 INSTITUTE OF RADIOELEMENT (IRE)
Chapter 8: Global Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Diagnostic Radiopharmaceuticals
8.2.2 Therapy Radiopharmaceuticals
8.2.3 Enriched Stable Isotopes
8.3 Historic and Forecasted Market Size By Application
8.3.1 Diagnostic Application
8.3.2 Therapeutic Application
8.3.3 Research
8.3.4 Pharmaceutical
8.3.5 Other
Chapter 9: North America Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Diagnostic Radiopharmaceuticals
9.4.2 Therapy Radiopharmaceuticals
9.4.3 Enriched Stable Isotopes
9.5 Historic and Forecasted Market Size By Application
9.5.1 Diagnostic Application
9.5.2 Therapeutic Application
9.5.3 Research
9.5.4 Pharmaceutical
9.5.5 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Diagnostic Radiopharmaceuticals
10.4.2 Therapy Radiopharmaceuticals
10.4.3 Enriched Stable Isotopes
10.5 Historic and Forecasted Market Size By Application
10.5.1 Diagnostic Application
10.5.2 Therapeutic Application
10.5.3 Research
10.5.4 Pharmaceutical
10.5.5 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Diagnostic Radiopharmaceuticals
11.4.2 Therapy Radiopharmaceuticals
11.4.3 Enriched Stable Isotopes
11.5 Historic and Forecasted Market Size By Application
11.5.1 Diagnostic Application
11.5.2 Therapeutic Application
11.5.3 Research
11.5.4 Pharmaceutical
11.5.5 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Diagnostic Radiopharmaceuticals
12.4.2 Therapy Radiopharmaceuticals
12.4.3 Enriched Stable Isotopes
12.5 Historic and Forecasted Market Size By Application
12.5.1 Diagnostic Application
12.5.2 Therapeutic Application
12.5.3 Research
12.5.4 Pharmaceutical
12.5.5 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Diagnostic Radiopharmaceuticals
13.4.2 Therapy Radiopharmaceuticals
13.4.3 Enriched Stable Isotopes
13.5 Historic and Forecasted Market Size By Application
13.5.1 Diagnostic Application
13.5.2 Therapeutic Application
13.5.3 Research
13.5.4 Pharmaceutical
13.5.5 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Diagnostic Radiopharmaceuticals
14.4.2 Therapy Radiopharmaceuticals
14.4.3 Enriched Stable Isotopes
14.5 Historic and Forecasted Market Size By Application
14.5.1 Diagnostic Application
14.5.2 Therapeutic Application
14.5.3 Research
14.5.4 Pharmaceutical
14.5.5 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Radiopharmaceuticals in Nuclear Medicine Scope:
|
Report Data
|
Radiopharmaceuticals in Nuclear Medicine Market
|
|
Radiopharmaceuticals in Nuclear Medicine Market Size in 2025
|
USD XX million
|
|
Radiopharmaceuticals in Nuclear Medicine CAGR 2025 - 2032
|
XX%
|
|
Radiopharmaceuticals in Nuclear Medicine Base Year
|
2024
|
|
Radiopharmaceuticals in Nuclear Medicine Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group, Isotec, Inc. (Sigma-Aldrich), Lantheus Medical Imaging, Inc., Nordion, Inc., Ntp Radioisotopes (Pty), Ltd., Siemens Healthcare (Subsidiary Of Siemens AG), Taiyo Nippon Sanso Corporation, Urenco Limited, Rotem Industries, Ltd., Inc., Australian Nuclear Association And Technology Organization (ANSTO), Board of Radiation And Isotope Technology (BRIT), Institute of Atomic Energy Polatom Radioisotope Centre, Institute of Isotopes Co., Ltd., Institute Of Radioelement (IRE).
|
|
Key Segments
|
By Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
By Applications
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
|
